This inventor holds 10 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Kabushiki Kaisha Yakult Honsha, Daiichi Pharmaceutical Co., Ltd.. Active years: 1990-2015.
Location History:
- Kanagawa-ken, JP (1998)
- Tokyo, JP (1990 - 2013)
- Minato-ku, JP (2015)
Company Filing History:
10 out of 214 
1 out of 200 Years Active: 1990-2015
Title: Takashi Yaegashi: Innovator in NFκB Inhibitors
Introduction
Takashi Yaegashi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit NFκB, a key player in inflammatory responses.
Latest Patents
Yaegashi holds a total of 10 patents, with his latest innovations focusing on phenanthroindolizidine compounds. These compounds are designed to provide an excellent NFκB inhibitory effect. Specifically, he has disclosed a compound represented by a complex formula, which includes various functional groups that enhance its efficacy as an active ingredient. His work in this area is crucial for developing new therapeutic options for diseases linked to NFκB activity.
Career Highlights
Throughout his career, Takashi Yaegashi has worked with notable companies such as Yakult Honsha Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.
Collaborations
Yaegashi has collaborated with esteemed colleagues, including Seigo Sawada and Tadashi Miyasaka. These partnerships have contributed to the advancement of his research and the successful development of innovative compounds.
Conclusion
Takashi Yaegashi's work in the field of NFκB inhibitors showcases his dedication to advancing pharmaceutical science. His innovative compounds hold promise for future therapeutic applications, making him a significant figure in the industry.